Efavirenz

ARV U.S. Brand Name

Sustiva

ARV Abbreviation(s)

EFV

U.S. FDA Label

Efavirenz Labeling (Package Insert)

ARV Class

Nonnucleoside reverse transcriptase inhibitors

First U.S. Approval

September 17, 1998

U.S. Manufacturer

Bristol Myers Squibb

Formulations

Strength	Formulation	Image	Description	Boosted
600 mg	Film-Coated Tablets Hard-gel Capsules	X	oval orange tablet with "Sustive" imprinted	No
200 mg	Film-Coated Tablets Hard-gel Capsules	X	oval orange tablet with "Sustive" and "200 mg" imprinted	No
50 mg	Film-Coated Tablets Hard-gel Capsules	X	Yellow and white capsule with "Sustiva" and "50 mg" imprinted	No

Generic Available?

Yes

FDCs

Efavirenz / Emtricitabine / Tenofovir DF

Efavirenz / Lamivudine / Tenofovir DF

Displaying 101 - 171 of 171

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Efavirenz Lorazepam 422	Green: Administer standard doses	Administer standard doses			2 mg x 1 dose	Lorazepam AUC no significant change; Cmax increased 16%
Efavirenz Lorazepam 421	Green: Administer standard doses	Administer standard doses			2 mg x 1 dose	Lorazepam AUC no significant change; Cmax increased 16%
Efavirenz Cetirizine 420	Green: Administer standard doses	Administer standard doses		No significant change	10 mg x 1 dose	Cetirizine Cmax decreased 24%
Efavirenz Cetirizine 419	Green: Administer standard doses	Administer standard doses		No significant change	10 mg x 1 dose	Cetirizine Cmax decreased 24%
Efavirenz Z-Pak 418	Green: Administer standard doses	Administer standard doses		No significant change	600 mg x 1 dose	Azithromycin AUC no significant change; Cmax increased 22%
Efavirenz Z-Pak 417	Green: Administer standard doses	Administer standard doses		No significant change	600 mg x 1 dose	Azithromycin AUC no significant change; Cmax increased 22%
Efavirenz LDV/SOF 416	Green: Administer standard doses	Administer standard doses			90 / 400 mg daily x 14 days	Ledipasvir / Sofosbuvir auc decreased 34%, Cmin decreased 34%, Cmax decreased 34%.
Efavirenz LDV/SOF 415	Green: Administer standard doses	Administer standard doses			90 / 400 mg daily x 14 days	Ledipasvir / Sofosbuvir auc decreased 34%, Cmin decreased 34%, Cmax decreased 34%.
Efavirenz LDV/SOF 414	Green: Administer standard doses	Administer standard doses			Ledipasvir 90 mg with sofosbuvir 400 mg daily	Ledipasvir AUC, Cmin, Cmax all decreased 34%; Sofosbuvir: no significant effect
Efavirenz Fluconazole 413	Green: Administer standard doses	Administer standard doses		AUC increased 16%; Cmax no significant change	200 mg x 7 days	No significant change
Efavirenz RAL 412	Green: Administer standard doses	Administer standard doses			400 mg x 1	Raltegravir AUC decreased 36%; Cmin decreased 21%; Cmax decreased 36%
Efavirenz Prednisolone 411	Green: Administer standard doses	Administer standard doses	Potential for increased prednisolone effects (adrenal insufficiency, Cushing?s syndrome).		20 mg x 1	Prednisolone AUC decreased 21%
Efavirenz RTV 410	Green: Administer standard doses	Administer standard doses	Increased efavirenz and ritonavir effects	Efavirenz AUC increased 21%; Cmax no significant change	500 mg Q12H x 8 days	Ritonavir AUC increased 18% after AM dose; Cmax increased 24% after AM dose; AUC no significant change after PM dose; Cmax no significant change after PM dose
Efavirenz RTV 409	Green: Administer standard doses	Administer standard doses	Increased efavirenz and ritonavir effects	Efavirenz AUC increased 21%; Cmax no significant change	500 mg Q12H x 8 days	Ritonavir AUC increased 18% after AM dose; Cmax increased 24% after AM dose; AUC no significant change after PM dose; Cmax no significant change after PM dose
Efavirenz Linagliptin 408	Green: Administer standard doses	Administer standard doses	Possible decrease in antihyperglycemic effects				Monitor glycemic control
Efavirenz Atorvastatin 407	Green: Administer standard doses	Administer standard doses	Decreased lipid effects	No significant change	10 mg daily x 5 days	Atorvastatin AUC decreased 43%; Cmax decreased 14%, Cmin decreased 69%. Atorvastatin and metabolites AUC decreased 32%, Cmin decreased 48%, Cmax decreased 15%	Monitor for statin efficacy. May need to increase atorvastatin dose
Efavirenz Atorvastatin 406	Green: Administer standard doses	Administer standard doses	Decreased lipid effects	No significant change	10 mg daily on days 0-3 and 15-18	Atorvastatin AUC decreased 43%; Atorvastatin and metabolites AUC decreased 34%	Monitor for statin efficacy. May need to increase atorvastatin dose
Efavirenz Atorvastatin 405	Green: Administer standard doses	Administer standard doses	Decreased lipid effects	No significant change	10 mg daily x 4 days	Atorvastatin AUC decreased 43%, Cmax decreased %14, cmin decreased 69% Atorvastatin and metabolites AUC decreased 32%	Monitor for statin efficacy. May need to increase atorvastatin dose
Efavirenz Buprenorphine / naloxone 404	Green: Administer standard doses	Administer standard doses	Possible decreased buprenorphine effects	No significant change	stable dose for at least 2 weeks	Buprenorphine AUC decreased 49%; Cmax decreased 45%, Cmin decreased 50%; half-life: decreased 29%	Monitor for signs and symptoms of opioid withdrawal; some patients may need an increase in the buprenorphine dose, though study patients did not go into opioid withdrawal
Efavirenz Sertraline 403	Green: Administer standard doses	Administer standard doses	Decreased sertaline effects		50 mg daily x 14 days		Monitor for signs and symptoms of depression and titrate sertaline to effect
Efavirenz Sertraline 402	Green: Administer standard doses	Administer standard doses	Decreased sertaline effects		50 mg daily x 14 days	Sertaline decreased 39%, Cmax decreased 29%, Cmin decreased 46%	Monitor for signs and symptoms of depression and titrate sertaline to effect
Efavirenz Sertraline 401	Green: Administer standard doses	Administer standard doses	Decreased sertaline effects	No significant change	50 mg daily x 14 days	Sertaline AUC decreased 39%, Cmax decreased 29%, Cmin decreased 46%	Monitor for signs and symptoms of depression and titrate sertaline to effect
Efavirenz Bupropion 400	Green: Administer standard doses	Administer standard doses	Decreased bupropion effects		150 mg SR x 1	Bupropion AUC decreased 55%; Cmax decreased 34%; half-life: decreased 46%	Monitor for signs and symptoms of depression and titrate bupropion to effect
Efavirenz Bupropion 399	Green: Administer standard doses	Administer standard doses	Decreased bupropion effects		150 mg SR x 1	Bupropion AUC decreased 55%; Cmax decreased 34%; half-life: decreased 46%	Monitor for signs and symptoms of depression and titrate bupropion to effect
Efavirenz Bupropion 398	Green: Administer standard doses	Administer standard doses	Decreased bupropion effects		150 mg SR x 1	Bupropion AUC decreased 55%; Cmax decreased 34%	Monitor for signs and symptoms of depression and titrate bupropion to effect
Efavirenz Isavuconazole 397	Green: Administer standard doses	Administer standard doses	Possible decreased Isavuconazole levels				monitor for isravucanazole concentrations and anti fungal response
Efavirenz DRV 396	Green: Administer standard doses	Administer standard doses	Potential for increased efavirenz effects	Efavirenz AUC increased 21%; Cmin increased 17%	300 mg BID with ritonavir 100 mg BID	Darunavir Cmin decreased 31%; Cmax decreased 15%; AUC decreased 13%	Monitor for increased risk of efavirenz related side effects. Consider monitoring drug levels
Efavirenz RIF 395	Green: Administer standard doses	Administer standard doses	Decreased efavirenz effects	Efavirenz AUC decreased 26%; Cmax decreased 20%, Cmin decreased 32%	600 mg x 7 days		Monitor for antiviral efficacy. May consider increasing efavirenz to 800 mg daily when used with rifampin
Efavirenz RIF 394	Green: Administer standard doses	Administer standard doses	Decreased efavirenz effects				Monitor for antiviral efficacy. May consider increasing efavirenz to 800 mg daily when used with rifampin
Efavirenz RIF 393	Green: Administer standard doses	Administer standard doses	Decreased efavirenz effects	Efavirenz AUC decreased 26%; Cmax decreased 20%	600 mg x 7 days		Monitor for antiviral efficacy. May consider increasing efavirenz to 800 mg daily when used with rifampin
Efavirenz RIF 392	Green: Administer standard doses	Administer standard doses	Decreased efavirenz effects	Efavirenz AUC decreased 22%; Cmax decreased 24%; Cmin decreased 25%	600 mg daily x 14 days	No significant change	Monitor for antiviral efficacy. May consider increasing efavirenz to 800 mg daily for patient's weighing 50 kg or more when used with rifampin
Efavirenz Diltiazem 391	Green: Administer standard doses	Administer standard doses	Decreased diltiazem effects	EFV AUC increased 11%, Cmax increased %16, Cmin increased 13%	240 mg daily x 14 days		Monitor diltiazem efficacy and to titrate to clinical effect
Efavirenz Diltiazem 390	Green: Administer standard doses	Administer standard doses	Decreased diltiazem effects	No significant change	240 mg daily x 21 days	Diltiazem AUC decreased 69%; Cmax decreased 60%; Cmin decreased 63%	Monitor diltiazem efficacy and to titrate to clinical effect
Efavirenz Diltiazem 389	Green: Administer standard doses	Administer standard doses	Decreased diltiazem effects	No significant change	240 mg daily x 21 days	Diltiazem AUC decreased 69%; Cmax decreased 60%; Cmin decreased 63%	Monitor diltiazem efficacy and to titrate to clinical effect
Efavirenz Diltiazem 388	Green: Administer standard doses	Administer standard doses	Decreased diltiazem effects	No significant change	240 mg daily x 21 days	Diltiazem AUC decreased 69%; Cmax decreased 60%; Cmin decreased 63%	Monitor diltiazem efficacy and to titrate to clinical effect
Efavirenz Voriconazole 387	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz		Efavirenz AUC increased 17%; Cmax no significant change	400 mg Q12H on days 2-7	Voriconazole Cmax increased 23%	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
Efavirenz Voriconazole 386	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz		Efavirenz AUC increased 17%; Cmax no significant change	400 mg Q12H on days 2-7	Voriconazole Cmax increased 23%	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
Efavirenz Voriconazole 385	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz	Increased efavirenz effects and decreased voriconazole effects	Efavirenz AUC increased 17%; Cmax no significant change	400 mg Q12H on days 2-7	Voriconazole Cmax increased 23%, AUC decreased 7%	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
Efavirenz Voriconazole 384	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz	Increased efavirenz effects and decreased voriconazole effects	Efavrenz AUC increased 44%; Cmax increased 38%	400 mg PO Q12H on day 1, then 200 mg Q12H on days 2-8	Voriconazole AUC decreased 77%; Cmax decreased 61%	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
Efavirenz Voriconazole 383	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz	Increased efavirenz effects and decreased voriconazole effects	Efavrenz AUC increased 44%; Cmax increased 38%	400 mg PO Q12H on day 1, then 200 mg Q12H on days 2-8	Voriconazole AUC decreased 77%; Cmax decreased 61%	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
Efavirenz Voriconazole 382	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz	Increased efavirenz effects and decreased voriconazole effects	Efavrenz AUC increased 44%; Cmax increased 38%	400 mg PO Q12H on day 1, then 200 mg Q12H on days 2-8	Voriconazole AUC decreased 77%; Cmax decreased 61%	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
Efavirenz Voriconazole 381	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz	Decreased voriconazole effects	No significant change	300 mg Q12H on days 2-7	Voriconazole AUC decreased 55%; Cmax decreased 36% (compared to voriconazole 200 mg BID)	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
Efavirenz Voriconazole 380	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz	Decreased voriconazole effects	No significant change	300 mg Q12H on days 2-7	Voriconazole AUC decreased 55%; Cmax decreased 36% (compared to voriconazole 200 mg BID)	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
Efavirenz Voriconazole 379	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz	Decreased voriconazole effects	No significant change	300 mg Q12H on days 2-7	Voriconazole AUC decreased 55%; Cmax decreased 36% (compared to voriconazole 200 mg BID)	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
Efavirenz Simvastatin 378	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of simvastatin	Decreased simvastatin effects	No significant change	40 mg daily x 4 days	Simvastatin AUC decreased 68%; Cmax decreased 72%; Cmin decreased 45%	Monitor statin efficacy. May need to increase simvastatin dose
Efavirenz Simvastatin 377	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of simvastatin	Decreased lipid effects	No significant change	40 mg daily on days 0-3 and 15-18	Simvastatin AUC decreased 58%	Monitor statin efficacy. May need to increase simvastatin dose
Efavirenz RFB 376	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin		Not studied	600 mg twice weekly	Rifabutin AUC no significant change; Cmax no significant change (when compared to rifabutin 300 mg twice weekly without efavirenz)	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
Efavirenz RFB 375	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Potential decreased rifabutin effects	Not studied	300 mg or 450 mg twice weekly	On 300 mg rifabutin twice weekly, rifabutin level 2 hours after dose: no significant change; rifabutin level 6 hours post dose: decreased 27%; on 450 mg twice weekly, rifabutin level 2 hours post dose: no significant change; rifabutin level 6 hours post dose: decreased 58%(all values compared to rifabutin alone)	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
Efavirenz RFB 374	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Decreased rifabutin effects	No significant change	300 mg daily x 14 days	Rifabutin AUC decreased 38%; Cmax decreased 32%; Cmin decreased 45%	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
Efavirenz RFB 373	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Decreased rifabutin effects	No significant change	300 mg daily x 14 days	Rifabutin AUC decreased 38%; Cmax decreased 32%; Cmin decreased 45%	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
Efavirenz RFB 372	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Decreased rifabutin effects	No significant change	300 mg daily x 14 days	Rifabutin AUC decreased 38%; Cmax decreased 32%	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
Efavirenz Pravastatin 371	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of pravastatin	Decreased pravastatin effects	No significant change	40 mg daily x 4 days	Pravastatin AUC decreased 44%; Cmax decreased 32%; Cmin decreased 19%	Monitor statin efficacy. May need to increase pravastatin dose
Efavirenz Pravastatin 370	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of pravastatin	Decreased lipid effects	No significant change	40 mg daily on days 0-3 and 15-18	Pravastatin AUC decreased 40%	Monitor statin efficacy. May need to increase pravastatin dose
Efavirenz Methadone 369	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	Decreased methadone effects (eg, withdrawal)		stable dose over period of 60 weeks	Methadone AUC decreased 39%; Cmax decreased 33%; Cmin decreased 44%EDDP (methadone metabolite) AUC decreased 14.5%; Cmax no significant change; Cmin no significant change	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose. In one study patients required mean dose increase of 30% over period of 60 weeks.
Efavirenz Methadone 368	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	Decreased methadone effects (eg, withdrawal)	Not studied		Methadone AUC decreased 57%; Cmax decreased 48%	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose. In one study patients required mean dose increase of 30% over period of 60 weeks.
Efavirenz Methadone 367	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	Decreased methadone effects (eg, withdrawal)		35-100 mg daily	Methadone AUC decreased 52%; Cmax decreased 45%	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose. In one study patients required mean dose increase of 30% over period of 60 weeks.
Efavirenz Methadone 366	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	Decreased methadone effects (eg, withdrawal)		35-100 mg daily	Methadone AUC decreased 52%; Cmax decreased 45%	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose. In one study patients required mean dose increase of 30% over period of 60 weeks.
Efavirenz Methadone 365	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	Decreased methadone effects (eg, withdrawal)		35-100 mg daily	Methadone AUC decreased 52%; Cmax decreased 45%	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose. In one study patients required mean dose increase of 30% over period of 60 weeks.
Efavirenz MVC 364	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Decreased maraviroc effects		100 mg BID	Maraviroc AUC decreased 45%; Cmax decreased 51%; Cmin decreased 45%	Increase maraviroc dose to 600 mg BID
Efavirenz MVC 363	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Decreased maraviroc effects		100 mg BID	Maraviroc AUC decreased 45%; Cmax decreased 51%; Cmin decreased 45%	Increase maraviroc dose to 600 mg BID
Efavirenz DTG 362	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of dolutegravir	Potentially reduced dolutegravir effectiveness		50 mg daily	Dolutegravir AUC decreased 57%; Cmin decreased 75%	If no INSTI resistance, increase dolutegravir dosage to 50 mg BID. If known or clinically suspected INSTI resistance, use alternative combination
Efavirenz Daclatasvir 361	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of daclatasvir	Potential loss of anti-HCV efficacy		120 mg daily	Daclatasvir Cmax increased 67%; AUC increased 37%.	Increase daclatasvir dose to 90 mg daily.
Efavirenz Fluvastatin 360	Yellow: Adjust dosing	adjust dosing to avoid increased levels of fluvastatin	Potential for increased levels of fluvastatin
Doravirine EFV 359	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Potential decrease in antiretroviral efficacy	AUC decreased 62%; Cmax decreased 35%; C24 decreased 85%	600 mg x 1	Not studied	Do not coadminister. Use alternative agents.
Doravirine EFV 358	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Potential decrease in antiretroviral efficacy	AUC decreased 32%; Cmax decreased 14%; C24 decreased 50%	600 mg daily x 14 days	Not studied	Do not coadminister. Use alternative agents.
Raltegravir EFV 288	Green: Administer standard doses	Administer standard doses	Potential decrease in antiretroviral efficacy	Raltegravir AUC decreased 36%; Cmax 36%; Cmin decreased 21%	600 mg daily	Not reported
Raltegravir EFV 287	Green: Administer standard doses	Administer standard doses	Potential decrease in antiretroviral efficacy	Raltegravir AUC decreased 14%	600 mg daily	Not reported
Dolutegravir EFV 89	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of dolutegravir	Potential decrease in antiretroviral efficacy	Cmax decreased 39%, AUC decreased 57%, Cmin decreased 75%	600 mg once daily	Not studied	Adjust dose of dolutegravir to 50 mg twice daily for treatment-naive and treatment experienced, INSTI naive adult patients, in pediatrics, increased the weight-based dose to twice daily, Use alternate combinations in INSTI experienced or INSTI resistance patients
Maraviroc EFV 36	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc		Maraviroc AUC increased 15%; Cmax increased 16% when compared to maraviroc 100 mg BID given alone.	600 mg daily	Not reported	Increase maraviroc dose to 600 mg BID. If including MVC, EFV plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
Maraviroc EFV 35	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Potential decrease in antiretroviral efficacy	Maraviroc AUC decreased 45%; Cmax decreased 51%	600 mg daily	Not reported	Increase maraviroc dose to 600 mg BID. If including MVC, EFV plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
Efavirenz

Subscribe to Efavirenz